The Problem of Cancer Drugs Costs: A Payer Perspective

Area of Science:

• Health Economics
• Oncology
• Health Policy

Background:

• Chemotherapy and supportive drugs represent a significant financial burden, accounting for 70% of cancer patient medical costs during active treatment.
• Payers employ various cost-containment strategies to manage these expenses, including financial incentives and administrative controls.
• Patient cost-sharing mechanisms are also utilized to transfer a portion of healthcare expenses to insured individuals.

Purpose of the Study:

• To review and analyze the strengths and weaknesses of current payer strategies for managing cancer drug costs.
• To explore the impact of potential policy changes on the future effectiveness of these cost-management approaches.

Main Methods:

• Review of existing payer strategies for managing oncology drug expenditures.
• Analysis of financial tools and administrative controls used by payers.
• Discussion of the influence of policy factors on cost management effectiveness.

Main Results:

• Payer strategies include lower margins for "buy and bill" oncologists, prior authorization, pathways, and performance-based compensation.
• Financial tools like deductibles, copayments, and coinsurance shift costs to patients.
• The effectiveness of payer strategies is influenced by drug competition, healthcare system monopolies, and FDA approval processes.

Conclusions:

• Current payer strategies offer partial solutions to high cancer drug costs but have limitations.
• Future policy changes regarding drug pricing, market exclusivity, and regulatory approvals will significantly impact the efficacy of cost-containment measures.
• A comprehensive approach considering both payer interventions and policy reforms is necessary for sustainable cost management in cancer care.